Ongoing Radioligand Trials May ‘Shift the Paradigm’ in Prostate Cancer


Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.

Combining 177Lu-PSMA-617 (Pluctivo) with other agents including androgen receptor (AR) pathway inhibitors may “further shift the treatment paradigm” for patients with metastatic castration-resistant prostate cancer (mCRPC), according to Scott T. Tagawa, MD, MS, FACP.

CancerNetwork® spoke with Tagawa, a professor of medicine and urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine, about ongoing clinical trials advancing 177Lu-PSMA-617 and similar compounds to earlier lines of treatment for mCRPC at the 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.


177Lu-PSMA-617 is being studied in early phases with combinations. In phase 3 trials, [investigators are] moving [it] earlier in terms of disease states. The PSMAfore trial [NCT04689828] has already read out in at least a press release form. In chemo-naive, metastatic CRPC after 1 line of AR pathway inhibitors, [investigators assessed] 177Lu-PSMA-617 in PET-selected patients versus second-line AR pathway inhibitors with a primary end point of radiographic progression-free survival and allowing for crossover. By press release, we know that’s positive and hopefully we’ll see the data in a few months.

And then 2 randomized studies, 1 randomized phase 2 and 1 randomized phase 3 study, are moving another disease state forward in terms of the castration-sensitive or hormone-sensitive population. The phase 3 trial called PSMAddition [NCT04720157] is [assessing] ADT [androgen deprivation therapy] plus AR pathway inhibitors with essentially early versus delayed 177Lu-PSMA-617. So it’s [3- versus 2-drug regimens], initially, with a primary end point of radiographic progression-free survival, but it also allowed them for crossover.

And then the Australian group is looking at ADT plus docetaxel alone or in a sequential fashion with 177Lu-PSMA-617. The same drug looks like it’s marching forward like we do with a lot of our successful drugs, and that will further shift the treatment paradigm.

In that mCRPC chemo-naïve disease state, there’s actually 4 phase 3 trials. First, the PSMAfore trial that I mentioned, and 2 trials of 177Lu-PSMA-I&T, a generic compound. There is one that’s called SPLASH [NCT04647526] and one that’s called ECLIPSE [NCT05204927]. [They are] very similar studies with slightly different dosing between the 2 agents. Second AR pathway inhibitors is the control arm, and the 177Lu-PSMA-I&T, which is very similar to 177Lu-PSMA-617, with radiographic progression-free survival as the primary end point generally with crossover allowed.

And then [investigators are evaluating] a different agent. The exact same target, PSMA, and the exact same radionuclide, lutieum-177, but with an antibody, formerly known as GF101 now called TLX-591. It is a similar type of a trial, except that it is an AR pathway inhibitor alone or an AR pathway inhibitor plus the lutetium PSMA antibody construct, also looking at radiographic progression-free survival. We have four different lutetium PSMA compounds in that first-line mCRPC disease state.


Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer. News release. Novartis. December 5, 2023. Accessed March 14, 2023.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Related Content